HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection.

MLA

Benedek, Gil, et al. “HLA-DRα1-MMOG-35-55 Treatment of Experimental Autoimmune Encephalomyelitis Reduces CNS Inflammation, Enhances M2 Macrophage Frequency, and Promotes Neuroprotection.” Journal of Neuroinflammation, vol. 12, June 2015, p. 123. EBSCOhost, https://doi.org/10.1186/s12974-015-0342-4.

APA

Benedek, G., Meza-Romero, R., Jordan, K., Keenlyside, L., Offner, H., & Vandenbark, A. A. (2015). HLA-DRα1-mMOG-35-55 treatment of experimental autoimmune encephalomyelitis reduces CNS inflammation, enhances M2 macrophage frequency, and promotes neuroprotection. Journal of Neuroinflammation, 12, 123. https://doi.org/10.1186/s12974-015-0342-4

Chicago

Benedek, Gil, Roberto Meza-Romero, Kelley Jordan, Lucy Keenlyside, Halina Offner, and Arthur A Vandenbark. 2015. “HLA-DRα1-MMOG-35-55 Treatment of Experimental Autoimmune Encephalomyelitis Reduces CNS Inflammation, Enhances M2 Macrophage Frequency, and Promotes Neuroprotection.” Journal of Neuroinflammation 12 (June): 123. doi:10.1186/s12974-015-0342-4.